Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Collegium Pharmaceutical ( (COLL) ) just unveiled an announcement.
On February 26, 2026, Collegium reported fourth-quarter 2025 net product revenues of $205.4 million, up 13% year over year, and record full-year 2025 revenues of $780.6 million, up 24%, driven by strong growth in ADHD drug Jornay PM and its pain portfolio. Jornay PM net revenue rose 57% in the quarter and 48% for 2025 to $148.9 million, prescriptions and prescribers hit all-time highs, and overall adjusted EBITDA reached record levels, supported by robust operating cash flow of $123 million in the quarter and cash and securities of $386.7 million at year-end.
The company’s pain franchise generated $159.6 million in quarterly revenue and a record $631.7 million for 2025, with Belbuca and the Nucynta franchise offsetting softer Xtampza ER sales, while a new authorized generic partnership with Hikma is expected to provide profit-sharing from Nucynta generics. Collegium also refinanced its debt with a $980 million syndicated credit facility, repurchased $25 million of shares and reaffirmed its 2026 guidance, signaling confidence in continued growth, balance-sheet strength and long-term value creation for shareholders and other stakeholders.
The most recent analyst rating on (COLL) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.
Spark’s Take on COLL Stock
According to Spark, TipRanks’ AI Analyst, COLL is a Outperform.
The score is driven primarily by solid underlying financial performance (strong margins and cash flow) and a notably positive earnings outlook with raised guidance. Offsetting factors include balance-sheet leverage risk and a relatively high P/E with no dividend yield, while technicals are constructive but not strongly bullish.
To see Spark’s full report on COLL stock, click here.
More about Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on treatments for attention deficit hyperactivity disorder and chronic pain. Its portfolio includes Jornay PM, a differentiated ADHD therapy, and a pain franchise led by Belbuca, Xtampza ER and the Nucynta products, targeting U.S. patients requiring extended-release and abuse-deterrent formulations.
Average Trading Volume: 444,087
Technical Sentiment Signal: Buy
Current Market Cap: $1.43B
For a thorough assessment of COLL stock, go to TipRanks’ Stock Analysis page.